Standard BioTools Announces Conference Call and Webcast of First Quarter 2022 Financial Results
Standard BioTools Inc. (Nasdaq:LAB) will announce its first quarter 2022 financial results on May 5, 2022, after market close. A conference call will be held at 2:00 p.m. PT to discuss these results and operational progress. Notably, the recent appointment of new management members follows a $250 million strategic capital infusion, leading to a 90-day assessment period without a Q&A session. The company focuses on advancing tools for biomedical research, highlighting its commitment to improving human health and efficiency in drug development.
- New management team appointed to drive strategic improvements.
- Company secured $250 million in strategic capital infusion.
- No Q&A session will follow the earnings call, limiting shareholder interaction.
SOUTH SAN FRANCISCO, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022, after the close of the market.
The Company’s management will host a conference call and webcast at 2:00 p.m. PT, 5:00 p.m. ET, on May 5, 2022, to discuss first quarter 2022 financial results and operational progress. A press release outlining the financial results will be publicly distributed before the call.
Individuals interested in listening to the conference call may do so by dialing:
US domestic callers: (877) 344-8082
Outside US callers: (213) 992-4618
Live audio of the webcast will be available online from the Investor Relations page of the Company’s website at Events & Presentations. The webcast will be archived on Standard BioTools Investor Relations page at investors.fluidigm.com and will be available until May 12.
Due to the appointment in April of new management team members who are focused on completing a 90-day assessment following the closing of a
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq:LAB), previously known as Fluidigm Corporation, is driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. Learn more at www.standardbiotools.com or connect with us on Twitter®, Facebook®, LinkedIn, and YouTube™. Standard BioTools, the Standard BioTools logo, Fluidigm, and the Fluidigm logo are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.
Available Information
Standard BioTools uses its website (standardbiotools.com), investor site (investors.standardbiotools.com), corporate Twitter account (@fluidigm), Facebook page (facebook.com/fluidigm), and LinkedIn page (linkedin.com/company/fluidigm-corporation) as channels of distribution of information about its products, its planned financial and other announcements, its attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and Standard BioTools may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Standard BioTools’ website and its social media accounts in addition to following its press releases, SEC filings, public conference calls, and webcasts.
Investors:
Peter DeNardo
415 389 6400
ir@fluidigm.com
FAQ
When will Standard BioTools report its financial results?
What time is the Standard BioTools earnings call?
What is the significance of the $250 million capital infusion for LAB?
Why won't there be a Q&A session after the earnings call?
